MedPath

A verification study of changes in blood amino acid levels with consumption of the protein drink

Not Applicable
Conditions
Healthy Japanese subjects
Registration Number
JPRN-UMIN000039280
Lead Sponsor
ORTHOMEDICO Inc.
Brief Summary

Kamioka Y, Miyazaki A, Takahashi Y, Takara T. Changes in Blood Amino Acid Levels after Consuming a Protein Drink with Kiwi Fruit Juice Powder-Randomized, Placebo-controlled, Double-blind, Crossover Trial-. Jpn Pharmacol Ther. 2020; 48(9): 1571-1587

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who have abnormal values in plasma amino acids fractionation 5. Subjects who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage in daily 6. Currently taking medicines (include herbal medicines) and supplements 7. Subjects who regularly use anticoagulants, such as warfarin 8. Subjects whose daily protein intake from protein drink is 25 g or more 9. Subjects who cannot stop the intake of protein drink other than the test food during this trial 10. Subjects who are planning to increase the amount of exercise during this trial 11. Subjects who are allergic to medicines and/or the test food related products, particularly milk, kiwi fruits, and latex 12. Subjects who have lactose intolerance 13. Subjects who are pregnant, breast-feeding, and planning to become pregnant 14. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to participate another trial during this trial 15. Subjects who are judged as ineligible to participate in the study by the physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath